close

Fundraisings and IPOs

Date: 2017-07-06

Type of information: Grant

Company: Evotec (Germany)

Investors: Hamburgische Investitions- und Förderbank (IFB Hamburg) (Germany)

Amount:

Funding type: grant

Planned used: The grant will be used to identify and develop therapeutic antibodies directed against novel immune-checkpoints on T-cells to improve future cancer treatments. It will fund a programme focused on demonstrating pre-clinical activity for at least one first-in-class antibody against novel immune-checkpoints active against patient-derived tumour cells. This EVT Innovate-anchored programme is designed to utilise synergies between Evotec’s infrastructure for the identification of novel therapeutic antibodies and Evotec’s collaboration partner, the University Medical Center Hamburg-Eppendorf , for the long-term understanding of immunological mechanisms, antibody-based cancer therapies and oncological screening.  

Others:  

  • • On July 6, 2017, Evotec announced that the company has been awarded a ‘Programm für Innovation’ (“PROFI”) grant for a period of two years from the Hamburgische Investitions- und Förderbank (IFB Hamburg), the central development institution of the Free and Hanseatic city of Hamburg, to identify and develop therapeutic antibodies directed against novel immune-checkpoints on T-cells to improve future cancer treatments.
  • The grant funding has been awarded under the IFB’s ‘Programm für Innovation’. The ‘Programm für Innovation’ was created to fund Hamburg-based R&D projects delivering novel or significantly improved products, processes or services across different disciplines. The grant will fund R&D work at Evotec and the UKE for a period of two-years.

Therapeutic area: Cancer - Oncology

Is general: Yes